TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
The management of vulval itching caused by benign vulval dermatoses
Key Statistics
- <5% — Cancer risk in lichen sclerosus
- 3 months — Clobetasol reducing course
- 30–60 g — Topical steroid used/year (maintenance)
Don't-miss facts
-
Itch = symptom not diagnosis – think dermatoses vs infection vs premalignant/malignant disease
-
Lichen sclerosus: <5% cancer risk – teach monthly self-examination
-
First-line for lichen sclerosus & lichen planus: superpotent topical steroid – clobetasol propionate 0.05%, 3-month reducing course (BAD)
-
Vulval vestibule mucosa is resistant to steroid atrophy; keratinised skin (labiocrural folds, perineum, thighs) is not
-
Apply topical steroid once daily as ointment; ~30–60 g/year maintenance use; teach the fingertip unit
-
Erosive lichen planus = painful (not itchy), scarring, poorly responsive – refer to vulval service
-
Biopsy: 4-mm Keyes punch, from lesion edge + normal tissue, under local anaesthetic; 2 biopsies needed if immunofluorescence required
-
Recurrent candidiasis (>6/year): fluconazole 100 mg weekly × 6 months; ≥50% relapse after stopping
Treatment failure checklist
Poor adherence/steroid phobia Wrong application site Continued irritant exposure
Incorrect diagnosis – biopsy if concerned
Abbreviation Key
- GP — general practitioner
- BASHH/BAD — British Association of Dermatologists
- NICE — National Institute for Health and Care Excellence
- NIHR — National Institute for Health Research
- VIN — vulval intraepithelial neoplasia
Source: Nunns D et al. The management of vulval itching caused by benign vulval dermatoses. The Obstetrician & Gynaecologist 2017;19:307–315. doi:10.1111/tog.12438
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).